Aduromed MedClean System Sold to New York Methodist Hospital


BETHEL, Conn., April 2, 2008 (PRIME NEWSWIRE) -- Aduromed Industries Inc. (OTCBB:ADRM) a leading manufacturer of medical waste treatment systems, today announced the sale of its MC4 Series system to New York Methodist Hospital, a member of the New York-Presbyterian Healthcare System. This MedClean(r) system will be installed at the Brooklyn, New York facility to replace a competitor's aging on-site technology and is expected to treat over 500,000 pounds of medical waste annually. This sale of the technologically superior MedClean Series solution increases Aduromed's presence in the mid-Atlantic corridor and follows the recently announced sale of a system in Baltimore.

"Aduromed's family of MedClean System users continues to grow as our marquee client list is enhanced with the addition of New York Methodist Hospital," said Damien R. Tanaka, CEO and President of Aduromed. "We truly appreciate New York Methodist's selection of our technology, and the replacement of previously installed competitor equipment demonstrates that this facility saw the enhanced benefits of our value proposition. Efficacious, cost-efficient, safe, and environmentally friendly treatment of medical waste is increasingly more important to healthcare institutions, and Aduromed remains committed to providing these benefits through its technology."

About Aduromed Corporation

Aduromed Industries, Inc., through its wholly-owned subsidiary, Aduromed Corporation, is a provider of innovative systems for the onsite treatment and disposal of regulated medical waste. Aduromed's flagship MedClean(r) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste.

Aduromed was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further information on Aduromed can be found at www.aduromed.com and in filings with the Securities and Exchange Commission found at www.sec.gov.

Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC on March 31, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.


            

Contact Data